Page 4 - Drug Pricing Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Healthcare

An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers. At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program. The U.S. Court of Appeals for the District of Columbia has said that they can. The May 21 ruling issued by Circuit Court Judge Gregory Katsas found for Novartis Pharmaceuticals

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.

A battle between the Arkansas Insurance Department and pharmaceutical manufacturers is heating up with the announcement of a hearing this summer to consider administrative penalties against AstraZeneca Pharmaceuticals LP, the drug manufacturing giant that filed a lawsuit against the state earlier this year over Act 1103 of 2021 -- the 340B Drug Pricing Nondiscrimination Act.